Question · asked by 1 review
Rofecoxib vs naproxen: Withdrawals due to adverse events
- Population
- children and adolescents with chronic non‐cancer pain
- Intervention
- Rofecoxib
- Comparison
- naproxen
- Outcome
- Withdrawals due to adverse events
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Rofecoxib vs naproxen Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents (2017) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 310 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.